NEW YORK (GenomeWeb News) – Agilent Technologies said after the close of the market Friday that it has completed the roughly $1.5 billion acquisition of Varian.
Completion of the deal was announced a day after Agilent said that the European Commission has informed the firm that it had met the conditions set forth in January for the acquisition of Varian. Those conditions included the divestiture of certain product lines, which were recently sold to Bruker.
Agilent said today that the majority of Varian's product lines will become part of the Chemical Analysis Group, with some key businesses being housed in Agilent's Life Sciences Group. Adding to Agilent's portfolio of mass spectrometry, liquid and gas chromatography, and array products, the firm's life sciences business gains Varian's nuclear magnetic resonance, MRI, and X-ray products.
"These technology platforms will open new doors for Agilent and its customers," Nick Roelofs, Agilent's senior VP and president of LSG, said in a statement. "This technology will play a key role in Agilent's growth through applications such as pharmaceutical and therapeutics."
Agilent is scheduled to report its second-quarter 2010 financial results after the close of the market today.